1. Home
  2. EDAP vs ANL Comparison

EDAP vs ANL Comparison

Compare EDAP & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDAP
  • ANL
  • Stock Information
  • Founded
  • EDAP 1979
  • ANL 2004
  • Country
  • EDAP France
  • ANL Cayman Islands
  • Employees
  • EDAP N/A
  • ANL N/A
  • Industry
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ANL
  • Sector
  • EDAP Health Care
  • ANL
  • Exchange
  • EDAP Nasdaq
  • ANL Nasdaq
  • Market Cap
  • EDAP 88.7M
  • ANL 81.9M
  • IPO Year
  • EDAP 1997
  • ANL 2023
  • Fundamental
  • Price
  • EDAP $2.15
  • ANL $1.94
  • Analyst Decision
  • EDAP Strong Buy
  • ANL Strong Buy
  • Analyst Count
  • EDAP 2
  • ANL 2
  • Target Price
  • EDAP $11.75
  • ANL $9.00
  • AVG Volume (30 Days)
  • EDAP 180.2K
  • ANL 6.0K
  • Earning Date
  • EDAP 03-27-2025
  • ANL 04-08-2025
  • Dividend Yield
  • EDAP N/A
  • ANL N/A
  • EPS Growth
  • EDAP N/A
  • ANL N/A
  • EPS
  • EDAP N/A
  • ANL N/A
  • Revenue
  • EDAP $66,378,507.00
  • ANL $5,000,000.00
  • Revenue This Year
  • EDAP $16.46
  • ANL N/A
  • Revenue Next Year
  • EDAP $14.30
  • ANL N/A
  • P/E Ratio
  • EDAP N/A
  • ANL N/A
  • Revenue Growth
  • EDAP 6.11
  • ANL N/A
  • 52 Week Low
  • EDAP $1.96
  • ANL $1.85
  • 52 Week High
  • EDAP $8.50
  • ANL $17.48
  • Technical
  • Relative Strength Index (RSI)
  • EDAP 39.79
  • ANL 33.94
  • Support Level
  • EDAP $1.96
  • ANL $2.05
  • Resistance Level
  • EDAP $2.57
  • ANL $2.49
  • Average True Range (ATR)
  • EDAP 0.24
  • ANL 0.17
  • MACD
  • EDAP -0.02
  • ANL -0.03
  • Stochastic Oscillator
  • EDAP 31.15
  • ANL 13.85

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: